Lorus Therapeutics has received first Japanese patent for its small molecule anticancer drug LOR-253 that will provide Lorus with exclusive rights to LOR-253 in Japan until 2023.
The patent will provide protection for LOR-253 composition of matter along with the coverage of Lorus lead antimicrobial small molecule LOR-220, which is used to treat drug resistant bacterial infections.
Lorus president and CEO Aiping Young said the Japanese patent is an addition to the Lorus global IP portfolio.
"Japan is a large and important market for drug therapies, and we believe this new patent should enhance partnering opportunities for both LOR-253 and LOR-220," Young added.
LOR-253 has been optimized to inhibit the cancer target Metal-Responsive Transcription Factor 1 (MTF-1) while LOR-220 targets a class of novel bacterial proteins called kinases.
